Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection

Lorenza N C Dezanet, Sarah Maylin, Audrey Gabassi, Hayette Rougier, Patrick Miaillhes, Caroline Lascoux-Combe, Julie Chas, Pierre-Marie Girard, Constance Delaugerre, Karine Lacombe, et al.

► To cite this version:

Lorenza N C Dezanet, Sarah Maylin, Audrey Gabassi, Hayette Rougier, Patrick Miaillhes, et al.. Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection. *Journal of Infectious Diseases*, 2020, 221 (11), pp.1826-1837. 10.1093/infdis/jiaa013 . hal-02886368

HAL Id: hal-02886368

<https://hal.sorbonne-universite.fr/hal-02886368>

Submitted on 1 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Kinetics of hepatitis B core-related antigen and anti-hepatitis B core antibody and their association with serological response in HIV-hepatitis B co-infection

Running head: Novel biomarkers in HBV-HIV co-infection

Lorenza N. C. Dezanet¹, Sarah Maylin², Audrey Gabassi², Hayette Rougier³, Patrick Mialhes⁴, Caroline Lascoux-Combe⁵, Julie Chas⁶, Pierre-Marie Girard⁷, Constance Delaugerre², Karine Lacombe^{1,7}, Anders Boyd^{1,7}

Institutional affiliations:

¹Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, F75012, Paris, France

²APHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, France; Université de Paris, INSERM U944, Institut de Recherche Saint-Louis, F75010, Paris, France

³IMEA, Institut de Médecine et d'Epidémiologie Appliquée, Paris, F75018, France

⁴Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Service de Maladies Infectieuses, Lyon, F69317, France

⁵APHP, Hôpital Saint-Louis, Service de Maladies Infectieuses, Paris, F75010, France

⁶APHP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, F75020, France

⁷APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, F75012, France

Main point:

Serum quantification of Hepatitis B core-related antigen and anti-Hepatitis B core antibodies could be useful in predicting HBeAg-seroclearance in HIV-HBV co-infected patients undergoing long-term

TDF-containing ART. Nevertheless, we emphasize that their performance is not better than other, currently available markers.

Corresponding author:

Dr. Anders Boyd

Services de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine

184 Rue du Faubourg St. Antoine, 75571 Paris Cedex 12, France

Tel: +33 1 71 97 05 17

Fax: +33 1 49 28 21 49

Email: anders.boyd@iplesp.upmc.fr

Alternate corresponding author:

Prof. Karine Lacombe

Services de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine

184 Rue du Faubourg St. Antoine, 75571 Paris Cedex 12, France

Tel : +33 1 49 28 31 96

Fax: +33 1 49 28 21 49

Email : karine.lacombe2@aphp.fr

Word count: Abstract – 199; Text – 3438

Abstract

Background: To describe the kinetics of hepatitis B core-related antigen (qHBcrAg) and anti-hepatitis B core antibody (qAnti-HBc) during tenofovir (TDF)-treatment and assess their ability to predict HBeAg-seroclearance in patients co-infected with HIV and hepatitis B virus (HBV).

Methods: Serum qHBcrAg, qAnti-HBc and HBV-DNA were obtained at TDF-initiation and every 6-12 months. On-treatment kinetics of qHBcrAg (Δ qHBcrAg) and qAnti-HBc (Δ qAnti-HBc) were estimated using mixed-effect linear regression. Hazard ratios (HR) assessing the association between markers and HBeAg-seroclearance were calculated using proportional hazards regression and sensitivity (Se) and specificity (Sp) of marker levels in predicting HBeAg-seroclearance were assessed using time-dependent ROC curves.

Results: During a median 4.6 years, cumulative incidence of HBsAg-seroclearance and HBeAg-seroclearance were 3.2% (n=5/158) and 27.4% (n=26/95), respectively. Δ qHBcrAg was biphasic in HBeAg-positive (-0.051 and -0.011 $\log_{10}$ U/mL/month during ≤ 18 months and >18 months, respectively) and monophasic in HBeAg-negative patients. Δ qAnti-HBc was monophasic regardless of HBeAg-status. In HBeAg-positive patients, baseline qHBcrAg and qAnti-HBc levels were associated with HBeAg-seroclearance (adjusted-HR=0.48/ $\log_{10}$ U/mL; 95%CI=0.33-0.70 and unadjusted-HR=1.49/ $\log_{10}$ PEIU/mL; 95%CI=1.08-2.07, respectively). Cutoffs with the highest accuracy in predicting HBeAg-seroclearance at 36 months were qHBcrAg $<6.5 \log_{10}$ U/mL at month-24 (Se=1/Sp=0.58) and baseline qAnti-HBc $\geq 4.1 \log_{10}$ PEIU/mL (Se=0.42/Sp=0.81).

Conclusions: In co-infected patients undergoing TDF, qHBcrAg/qAnti-HBc could be of use in monitoring HBeAg-seroclearance.

Key words: hepatitis B; HIV; seroclearance; hepatitis B core-related antigen; anti-hepatitis B core antibody.

Background

In HIV-positive individuals, it was recently estimated that 7.4% worldwide were co-infected with chronic hepatitis B virus (HBV) [1]. HIV-HBV co-infection has been associated with increased risk of liver cirrhosis, hepatocellular carcinoma, and hepatic decompensation particularly when HBV replication is left uncontrolled [2,3]. Tenofovir (TDF)-containing antiretroviral therapy (ART) effectively provides dual activity against HIV and HBV in co-infected patients, allowing suppression of HBV replication [4]. Wide-spread TDF use in co-infected patients has led to substantial decreases in HBV-DNA detection, with almost 85% of patients able to achieve undetectable HBV-DNA [5].

In HBV mono-infected patients, the viral markers indicating improved prognosis are suppression of HBV-DNA, hepatitis B “e” antigen (HBeAg) seroclearance (for those with HBeAg-positive serology), and more importantly hepatitis B surface antigen (HBsAg) seroclearance [4]. During TDF use in HIV-HBV co-infected patients, almost half of those who are HBeAg-positive exhibit HBeAg-seroclearance and few overall have HBsAg-seroclearance [6,7]. There are, however, exceptions in which higher rates of seroclearance are observed in co-infected patients with more severe immunosuppression [8–10]. As antiviral therapy inhibits viral replication of HBV-DNA, its levels do not accurately reflect intrahepatic HBV activity in patients undergoing antiviral treatment [11]. Other markers of treatment efficacy, such as quantification of HBeAg (qHBeAg) and HBsAg (qHBsAg), have been useful in predicting seroclearance events, but their stability during long-term treatment makes their use in routine clinical practice debatable [6,12].

Recently, quantitative hepatitis B core-related antigen (qHBcrAg) and anti-hepatitis B core antibody (qAnti-HBc) have been gaining attention in HBV mono-infection. qHBcrAg consists of three proteins, hepatitis B core antigen (HBcAg), HBeAg and a 22KDa *precore* protein (p22cr), which are transcribed from the *precore/core* gene and share an identical 149 amino acid sequence [13]. This surrogate marker strongly correlates with covalently-closed circular (ccc)DNA and total intrahepatic HBV-DNA during antiviral-induced HBV suppression [13–18]. qAnti-HBc involves quantification of the standard marker anti-HBc antibodies and is thought to reflect HBV-specific adaptive immunity. Baseline levels of this marker have been shown to bear reliable prediction of HBeAg seroconversion in HBV mono-infected patients undergoing antiviral therapy [19].

Nevertheless, current research on these markers has mainly focused on HBV mono-infected patients, while no study to date has examined its relevance in HIV-HBV co-infection. This is particularly concerning as qAnti-HBc levels are linked to host immunity [20], which could be impaired during HIV infection. The aim of the present study was to describe qHBcrAg and qAnti-HBc kinetics during long-term TDF treatment in a large, prospective cohort of ART-experienced HIV-HBV co-infected patients. We further aimed to evaluate the association between these markers and HBeAg or HBsAg-seroclearance and their predictive capacity for these events.

Methods

Patients and data collection

Patients were selected from the French HIV-HBV Cohort Study [21]. Briefly, this prospective study recruited 308 HIV-infected patients with chronic HBV infection from seven clinical

centers located in Paris and Lyon, France during May 2002–May 2003. Patients were included if they had HIV-positive serology confirmed by western blot and HBsAg-positive serology for more than 6 months. Participants were followed prospectively every six to twelve months until 2010-2011.

For this analysis, we included patients who initiated TDF-containing ART, had a minimum of two consecutive visits undergoing TDF-containing ART (lasting more than 6 months), with an available sample at TDF-initiation and at least once during follow-up. Patients with detectable HCV-RNA or HDV-RNA or those undergoing intensification with standard or pegylated-interferon (peg-IFN) were excluded from analysis (Supplementary figure 1). All patients gave written informed consent to participate in the cohort and the study received ethical approval in accordance with the Helsinki declaration.

Baseline was defined as the study visit at or directly prior to TDF-initiation. Follow-up began at TDF-initiation and continued until last study visit, TDF discontinuation, meeting any one of the exclusion criteria, or death; whichever occurred first. Demographic information were collected at study inclusion. HIV- and HBV-related variables were collected before TDF initiation and at each follow-up visit.

Assessing markers of viral activity

Serum HBV-DNA was quantified at baseline and every 6 months by a real-time PCR assay (COBAS® AmpliPrep/COBAS TaqMan®, detection limit: 12 IU/mL; or COBAS® Amplicor HBV Monitor, detection limit: 60 IU/mL; Roche Diagnostics, Meylan, France). HIV-RNA viral load was measured at cohort inclusion and every six months using either a branched-DNA (b-DNA Quantiplex 3.0, detection limit: 50 copies/mL, Bayer Diagnostics, Cergy Pontoise, France) or

real-time PCR technique (COBAS® AmpliPrep/COBAS TaqMan® HIV-1 test, detection limit: 40 copies/mL, Roche Molecular Systems, Meylan, France).

Qualitative HBsAg, HBeAg, and antibodies were detected yearly using commercial enzyme-linked immunoassays (EIAs) (Diasorin, Antony, France). All other markers were collected at baseline and every 6 months. Serum qHBsAg levels (IU/mL) were quantified using the ARCHITECT HBsAg assay (Abbott Laboratories, Rungis, France) [7,22]. Serum qHBeAg levels were quantified using either ARCHITECT or Elecsys HBeAg assay (with Modular E170 analyzer; Roche Diagnostics). qHBeAg levels were expressed in Paul Ehrlich Institute units (PEIU)/mL [23]. qHBcrAg (U/mL) was measured using a commercially-available, automated HBcrAg chemiluminescence EIA (Lumipulse® G System, FujiRebio Europe, Gent, Belgium) [24]. When initial qHBcrAg levels were above $7 \log_{10}$ U/mL, a 1/100 dilution was performed to obtain results within the range of quantification. Finally, IgG and IgM anti-HBc antibodies were quantified using ARCHITECT Anti-HBc II assay (Abbott Laboratories, Rungis, France) with an automated ARCHITECT i4000 system. Anti-HBc antibody levels were reported in PEIU/mL [25].

Statistical analysis

All qHBcrAg and qAnti-HBc units were $\log_{10}$ transformed. Linear regression was used to estimate univariable differences in baseline qHBcrAg or qAnti-HBc, and their 95% confidence intervals (CI), across levels of determinants. A multivariable model was constructed by adding all covariables with a $p < 0.2$ in univariable analysis and removing non-significant variables in backwards-stepwise fashion.

In longitudinal analysis, on-treatment kinetics of the changes of qHBcrAg (Δ qHBcrAg) and qAnti-HBc (Δ qAnti-HBc) were estimated using mixed-effect linear regression models with a

random-intercept to account for between-patient variability at baseline [26]. Models were stratified by HBeAg-status. Given the bi-phasic nature of Δ qHBcrAg kinetics among HBeAg-positive patients in preliminary analysis, we modeled qHBcrAg kinetics according to ≤ 18 and > 18 months of TDF treatment. All of the models were adjusted *a priori* for factors influencing liver fibrosis or HBV replication: body mass index (BMI), age, concomitant lamivudine (LAM) treatment, cumulative treatment duration with LAM, undetectable HBV-DNA, CD4+ cell count > 350 cells/mm³ (if not already stratified), and baseline qHBcrAg or qAnti-HBc levels. For specific genetic and immunological determinants, we also included a cross-product term between TDF duration and presence of determinant along with its individual components (separately for each determinant), from which stratum-specific estimates could be calculated and differences in Δ HBcrAg and Δ qAnti-HBc could be tested.

We then evaluated the relationship between qHBcrAg or qAnti-HBc and HBeAg-seroclearance. First, univariable hazards ratios (HR) and 95%CI comparing hazards of HBeAg-seroclearance between continuous baseline levels of markers (qHBcrAg and qAnti-HBc separately) were estimated using Cox proportional hazards models. A multivariable model was constructed using the backwards-selection approach as described above. Second, we performed several analyses to explore the most adequate thresholds for both markers, individually or combined. We selected the following criteria to assess the predictive capacity of HBeAg-seroclearance: qHBcrAg $\log_{10}$ U/mL < 7.5 at baseline and < 6.5 at months 12, 24 and 36; qAnti-HBc $\geq 4.1 \log_{10}$ PEIU/mL at baseline; qHBcrAg $< 7.5 \log_{10}$ U/mL and qAnti-HBc $\geq 4.1 \log_{10}$ PEIU/mL at baseline; qHBcrAg $< 7.5 \log_{10}$ U/mL or qAnti-HBc $\geq 4.1 \log_{10}$ PEIU/mL at baseline; and HBV-DNA < 60 IU/mL at months 12, 24 and 36. Time-dependent receiver operating characteristic (ROC) curves were used to evaluate the sensitivity (Se) and specificity (Sp) of each criterion as predictor of HBeAg-seroclearance until specific time-points of TDF duration [27].

All statistical analysis was performed using STATA (v15.1, College Station, TX, USA) or RStudio (v1.1.453, Vienna, Austria) and significance was defined as a p -value <0.05 .

Results

Baseline characteristics of the study population

Of the 158 patients, 95 (60%) were HBeAg-positive and 63 (40%) HBeAg-negative. At TDF-initiation, median age was 41.1 years (IQR=35.5-48.0) and the majority was male (84.2%). All patients were ART-experienced with median CD4⁺ cell count at 404/mm³ (IQR=295-552) and 57.3% ($n=90$) having undetectable HIV-RNA. A total of 123 (78.3%) had detectable HBV-DNA with a median viral load of 5.2 log₁₀ IU/mL (IQR=3.0-7.2). For those with available data on HBV genotypes, most patients harbored genotype A (68%), followed by E (12%), G (12%) and D (8%). The G to A nucleotide substitution at position 1896 of the *precore* region was identified in 21.8% of patients ($n=22/101$).

As shown in Table 1, HBeAg-positive patients were more often male ($p<0.001$), born in zone of low/moderate HBV-prevalence ($p<0.001$), diagnosed with an AIDS-defining event ($p=0.04$), had a longer duration of known HIV-infection ($p=0.007$), higher levels of HIV-RNA ($p=0.03$) and qHBsAg ($p<0.001$) than HBeAg-negative patients (Table 1). As expected, HBV-DNA and ALT/AST levels were higher among HBeAg-positive versus HBeAg-negative patients (both $p<0.001$).

Baseline determinants of qHBcrAg and qAnti-HBc levels

At TDF-initiation, median levels of unadjusted qHBcrAg were significantly higher in HBeAg-positive (7.8 log₁₀ U/mL; IQR=7.0-8.2; $p<0.001$) versus HBeAg-negative patients (3.0 log₁₀ U/mL; IQR=2.5-4.0), while median levels of unadjusted qAnti-HBc were greater in HBeAg-

negative ($3.4 \log_{10}$ PEIU/mL; IQR=3.0–3.9; $p=0.008$) versus HBeAg-positive patients ($2.8 \log_{10}$ PEIU/mL; IQR= 1.1–4.0) (Table 1). In multivariable analysis (Table 2), baseline qHBcrAg levels (adjusted mean $\log_{10}$ U/mL) were higher in those with an AIDS-defining event (6.3 versus without advanced HIV disease, 5.7; $p=0.06$), ALT >70 IU/L (6.7 versus ALT $\leq$ 70 IU/L, 5.5; $p<0.001$) and higher serum HBV-DNA ($p<0.001$). Baseline qAnti-HBc levels (adjusted mean $\log_{10}$ PEIU/mL) were higher in older individuals ($p=0.09$), those without an AIDS-defining illness (3.0 versus with AIDS-defining illness, 2.3; $p=0.047$), with higher CD4+ cell count ($p<0.001$) and with HBeAg-negative status at baseline (3.4 versus HBeAg-negative, 2.5; $p<0.001$).

On-treatment kinetics of qHBcrAg and qAnti-HBc levels

Median follow-up of TDF treatment was 4.6 years (IQR=2.9-7.6). Adjusted Δ HBcrAg was faster in HBeAg-positive versus HBeAg-negative patients, overall and during the first 18-months of treatment (Table 3; figure 1A). In HBeAg-positive patients, adjusted Δ qHBcrAg during TDF treatment was biphasic, with a significantly more rapid decline during the first 18 months ($-0.051 \log_{10}$ U/mL/month) compared to thereafter ($-0.011 \log_{10}$ U/mL/month; $p=0.007$). In HBeAg-negative patients, adjusted Δ qHBcrAg was linear during TDF treatment ($-0.003 \log_{10}$ U/mL/month). Δ qHBcrAg was faster in HBeAg-negative patients with HBV genotype D infection ($p<0.001$) and slower with genotype A infection ($p=0.01$) compared to other genotypes, while faster Δ qHBcrAg was observed in HBeAg-negative patients with *precore* mutations compared to without ($p=0.009$).

Both HBeAg-positive and HBeAg-negative patients had linear Δ qAnti-HBc during TDF treatment (Figure 2A), while Δ qAnti-HBc was not different between HBeAg-positive versus HBeAg-negative patients ($-0.011 \log_{10}$ PEIU/mL/month for both; $p=0.7$) (Table 3). In HBeAg-positive patients, adjusted Δ qAnti-HBc was significantly faster in HBV genotype A versus non-A

infection ($p=0.02$). In both HBeAg-positive and HBeAg-negative patients, those with CD4+ cell count $>350/\text{mm}^3$ versus $\leq 350/\text{mm}^3$ and those with a nadir CD4+ cell count $>200/\text{mm}^3$ versus $\leq 200/\text{mm}^3$ exhibited a significantly faster $\Delta\text{qAnti-HBc}$ during TDF treatment (Table 3).

Of note, baseline qHBsAg levels were not significantly correlated with individual $\Delta\text{qHBcrAg}$ in HBeAg-positive individuals (Bland-Altman $\rho=-0.06$, $p=0.11$) and HBeAg-negative individuals (Bland-Altman $\rho=0.0004$, $p=0.9$). Baseline qHBsAg levels were also not significantly correlated with individual $\Delta\text{qAnti-HBc}$ in HBeAg-positive individuals (Bland-Altman $\rho=0.06$, $p=0.12$) and HBeAg-negative individuals (Bland-Altman $\rho=-0.08$, $p=0.12$).

Association of qHBcrAg and qAnti-HBc levels with seroclearance

During TDF treatment, 26 HBeAg-positive patients achieved HBeAg-seroclearance (cumulative incidence=27.4%, 95%CI=18.7%-37.5%). Of the patients with HBeAg-seroclearance, HBeAg seroconversion occurred in 8 (cumulative incidence=8.4%, 95%CI=3.7%-15.9%). Patients with lower baseline qHBcrAg level had a higher rate of HBeAg-seroclearance (Figure 1B) after adjusting for change in CD4+ cell count from previous visit (adjusted-HR=0.48, 95%CI=0.33–0.70) (Table 4). Patients with higher baseline qAnti-HBc level had higher rates of HBeAg-seroclearance (HR=1.49, 95%CI=1.08-2.07) (Figure 2B), while no other variable was below the p -value threshold considered for multivariable analysis (Table 4). In addition, $\Delta\text{qAnti-HBc}$ was also faster among patients achieving HBeAg-seroclearance during follow-up ($-0.017 \log_{10}$ PEIU/mL/month) compared to those without HBeAg-loss (-0.010 PEIU/mL/month; $p<0.001$).

HBsAg-seroclearance occurred in only 5 patients (cumulative incidence=3.2%, 95%CI=1.0%–7.2%). There were no statistically significant differences in their baseline characteristics compared to those without HBsAg-seroclearance (Supplementary table 1). Among those with

HBsAg-seroclearance, median baseline qHBcrAg was $6.7 \log_{10}$ U/mL (range HBeAg-positive=6.7-8.0, HBeAg-negative=3.7-4.0) and median baseline qAnti-HBc was $3.2 \log_{10}$ PEIU/mL (range HBeAg-positive=1.2-4.6, HBeAg-negative=1.8-3.6). Δ qHBcrAg appeared steeper during the first 12 months of TDF treatment in these individuals (Figure 1C), while the change in qAnti-HBc was flat during follow-up (Figure 2C). Given the few numbers of patients with HBsAg-seroclearance, this endpoint was not considered further in analysis.

Predictive capacity of HBV serological markers on HBeAg-seroclearance

Table 5 gives the Se and Sp of various criteria in predicting HBeAg-seroclearance at specific time-points during TDF treatment. As expected, undetectable HBV-DNA for most time-points provided optimal Se, but consistently low Sp in predicting long-term HBeAg-seroclearance. qHBcrAg $<6.5 \log_{10}$ U/mL at months 12, 24 or 36 showed comparable Se to undetectable HBV-DNA, but higher Sp especially for predicting HBeAg-seroclearance in the 12 months following qHBcrAg measurement. Baseline qAnti-HBc $\geq 4.1 \log_{10}$ PEIU/mL showed high Sp, but very low Se in predicting HBeAg-seroclearance. When combining qHBcrAg $<7.5 \log_{10}$ U/mL and qAnti-HBc $\geq 4.1 \log_{10}$ PEIU/mL, both assessed at baseline, we found the highest levels of Sp in predicting HBeAg-seroclearance of the studied markers, but low Se.

Discussion

Despite the extensive research on novel biomarkers of HBV viral activity, none to date have examined their kinetics or association with seroclearance in HIV-HBV co-infected patients undergoing TDF treatment. We have demonstrated a gradual decrease of on-treatment qHBcrAg and qAnti-HBc levels, compatible with a cumulative therapeutic benefit of long-term nucleos(t)ide analogue (NA) therapy. Our findings indicated that lower baseline levels of qHBcrAg and higher qAnti-HBc antibodies were strong, independent predictors of HBeAg

seroclearance, suggesting some clinical applicability in TDF-treated HIV-HBV co-infected patients. To our knowledge, this study is the first to report the clinical utility of qHBcrAg or qAnti-HBc levels as a predictor of HBeAg-seroclearance in the treated HIV-HBV co-infected population.

Despite the fact that all previous studies examining qHBcrAg and qAnti-HBc antibodies have been performed in HBV mono-infected patients, we did observe several similarities to our co-infected population [19,28]. A decrease in qHBcrAg during TDF treatment was indeed observed for both HBeAg-positive or HBeAg-negative patients [28,29]. In addition, we demonstrated a bi-phasic decline in HBeAg-positive patients, which probably reflected the initial, effective inhibition of circulating virus in the blood associated with TDF followed by reductions of the cccDNA pool [30]. For qAnti-HBc antibodies, its kinetics in TDF-treated HIV-HBV coinfecting patients showed a steady decline, for both HBeAg-positive or HBeAg-negative patients, similar to HBV mono-infected individuals treated with peg-IFN or NAs [19,31,32]. Interestingly, the observation of higher median baseline qAnti-HBc levels in HBeAg-negative versus HBeAg-positive patients could be the result of increased immune activity in patients previously able to clear HBeAg [33,34].

We were able to identify other viral characteristics associated with qHBcrAg and qAnti-HBc kinetics. The presence of a *precore* mutation in HBeAg-negative patients appeared to accelerate declines in qHBcrAg. Indeed, as *precore* mutations can block the synthesis of HBeAg without adversely affecting HBV replication [35], the more rapid decrease in qHBcrAg might partly reflect viral suppression linked to TDF treatment. Whether this is due to reduction of the cccDNA pool in hepatocytes or from immunological clearance of virus in patients harboring *precore* mutant variants is unknown and cannot be confirmed with the data collected in our

study. Nevertheless, it should be noted that the rates of declines observed in these patients were much slower than most of the average rates of declines in HBeAg-positive patients.

On-treatment qAnti-HBc kinetics were faster in HBV genotype A versus non-A genotypes, specifically among HBeAg-positive patients. In studies on the natural history of HBV mono-infection, HBeAg-positive patients with HBV genotype A have demonstrated higher rates of sustained transaminase normalization, HBV-DNA clearance, transition to inactive HBV carrier state after HBeAg-seroconversion, and HBsAg-seroclearance [36,37]. These data would suggest that a more robust antiviral immune response could be elicited against genotype A infection, yet the exact mechanisms remain unknown ([38]). The faster decrease in qAnti-HBc levels builds on these findings, suggesting that anti-HBV-specific immunity could be more active in HBeAg-positive genotype A infected patients, even during TDF treatment.

Interestingly, given that HIV-related immunity also exerts an effect on anti-HBV-specific immunity [39], qAnti-HBc levels would assumedly be influenced by the degree of HIV-induced immunosuppression. This effect was already apparent at baseline, at which point qAnti-HBc levels were lower in patients with a previous AIDS-defining illness and lower CD4+ T cell counts. Additionally, more rapid declines of qAnti-HBc were observed in patients with higher baseline (>350 cells/mm³) and nadir (>200 cells/mm³) CD4+ cell counts, regardless of baseline HBeAg-status, supporting the concept that more pronounced immunosuppression lends to slower declines of qAnti-HBc [40]. How this translates to HBeAg-seroclearance is unclear. Faster slopes of qAnti-HBc were associated with HBeAg-seroclearance, suggesting that longer time spent at higher levels of qAnti-HBc levels (i.e. with more active anti-HBV immunity) does not lead to seroclearance. In addition, we observed no significant association with CD4+ cell counts and HBeAg-seroclearance.

More importantly, we found that higher levels of qHBcrAg at the time of initiating TDF-containing ART were independently associated with lower rates of HBeAg-seroclearance in HBeAg-positive patients. Previous research linking baseline qHBcrAg levels with HBeAg-seroclearance have mostly focused on treatment with peg-IFN. In 46 patients treated with peg-IFN, Chuaypen et al [18] reported that those with baseline qHBcrAg levels $>8 \log_{10}$ U/mL had a low risk of HBeAg seroclearance and suppression of HBV-DNA at 12 weeks post-treatment. Others have found that qHBcrAg levels at week 12 of peg-IFN treatment were predictive of post-treatment HBeAg-seroclearance [29], while another study investigating entecavir (ETV) with or without peg-IFN add-on therapy observed that higher qHBcrAg levels at both week 24 and week 36 were independently associated with a lower risk of HBeAg-seroclearance and HBV-DNA suppression 24-weeks post-treatment in both treatment arms [37]. With regards to NA-based therapy, baseline HBcrAg levels $>5.7 \log_{10}$ U/mL have been also associated with lack of HBeAg-seroconversion at 6 and 12 months of treatment [28] and faster declines of qHBcrAg were observed in patients with HBeAg-seroclearance as compared to those without [33]. Our findings in TDF-treated HIV-HBV co-infected patients fall in line with these studies.

Likewise, we found an association between anti-HBc antibody levels and HBeAg-seroclearance, indicating that patients with higher baseline total qAnti-HBc levels exhibited higher rates of HBeAg-seroclearance. Previous research has suggested that baseline qAnti-HBc strongly predicts HBeAg-seroconversion in populations of HBV mono-infected patients receiving either NA or peg-IFN therapy [19,25,32]. The fact that an association between qAnti-HBc levels and HBeAg-seroclearance was observed in HIV-HBV co-infected patients, given the effect of HIV-induced immunosuppression on its quantification and sometimes higher rates of HBeAg-seroclearance observed after anti-HBV containing ART [9,10], is noteworthy.

In terms of predictive capacity, we confirm the high sensitivity of qHBcrAg. We add to previous studies by showing that qHBcrAg levels have higher specificity in predicting HBeAg-seroclearance within 12-months of being measured, with waning specificity in predicting HBeAg-seroclearance thereafter. This finding implies that repeated measurements of qHBcrAg would be needed in order to continuously and more accurately gauge the risk of HBeAg-seroclearance. Indeed, other studies focusing on time-specific measurements of serum qHBcrAg levels have involved peg-IFN treatment in HBV mono-infected patients, with qHBcrAg measured at 12 weeks representing an important milestone for treatment response and stopping rules [18,29,41]. These studies have also demonstrated higher Se, but modest Sp when using qHBcrAg to predict HBeAg-seroconversion. On the other hand, serum anti-HBc antibodies had higher Sp at baseline than at any point during follow-up. Even when used as a complementary marker with qHBcrAg, predictive capacity did not improve. Nevertheless, the performance of these markers appears to be similar to qHBsAg and qHBeAg from previous studies in TDF-treated co-infected individuals [42]. Coupled with the marginally higher Sp when compared to using undetectable HBV-DNA to predict HBeAg-seroclearance, it is debatable to what extent these markers should be used in routine care (38).

Certain limitations of our study must be acknowledged. We only included analysis on HBeAg seroclearance and not HBeAg seroconversion, which could be considered a more desired endpoint of treatment response [4]. Considering that few patients achieved HBsAg seroclearance, our analysis on this endpoint was wholly descriptive. Second, there was substantial heterogeneity of HBcrAg levels observed during follow-up, making interpretability of this marker somewhat difficult. Finally, data on HBV genetic variability were available for patients with HBV-DNA replication, representing a group with more active HBV infection.

In conclusion, we provide a thorough understanding of qHBcrAg and qAnti-HBc kinetics, and their clinical applicability, in the context of HIV-HBV co-infection. Serum levels of qHBcrAg and qAnti-HBc could be useful in predicting HBeAg-seroclearance in HIV-HBV co-infected patients undergoing long-term TDF-containing ART. This is based on the high sensitivity of qHBcrAg and high specificity of qAnti-HBc, when compared to undetectable HBV-DNA, in predicting HBeAg-seroclearance. Nevertheless, whether they provide further clinical utility compared to qHBsAg and qHBeAg remains debatable.

Notes

Conflicts of interest statement. C.D. reports receiving grants outside the submitted work from ViiV and Gilead, and K.L. reports receiving advisory board fees from Gilead. All other authors have no potential conflicts of interest to report.

Funding. This work was supported by SIDACTION (AO 19); and the Agence nationale de recherches sur le Sida et les hépatites virales (ANRS). Gilead Sciences, Inc. provided an unrestricted grant for the French HIV-HBV cohort and was not involved in any part of the data collection, analysis and manuscript writing.

Meetings. These findings have been presented at the Réunion Annuelle AC42 - Réseau National Hépatites de l'ANRS 2019, in February 2019, held in Paris, France; and, at the EASL-AASLD HBV Endpoint Cure Conference, in March 2019, held in London, England (abstract numbers: P04-01YI and P04-02YI).

Acknowledgements. This study has been sponsored by the Institut de Médecine et d'Epidémiologie Appliquée (IMEA). L.D. was awarded a post-doctoral fellowship from the Agence nationale de recherches sur le Sida et les hépatites virales (ANRS).

Corresponding author. Dr. Anders Boyd
Services de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine
184 Rue du Faubourg St. Antoine, 75571 Paris Cedex 12, France
Tel: +33 1 71 97 05 17
Fax: +33 1 49 28 21 49
Email: anders.boyd@iplesp.upmc.fr

Alternate corresponding author. Prof. Karine Lacombe
Services de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine
184 Rue du Faubourg St. Antoine, 75571 Paris Cedex 12, France
Tel : +33 1 49 28 31 96
Fax: +33 1 49 28 21 49
Email : karine.lacombe2@aphp.fr

References

1. World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017. Available at: <http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1>. Accessed 07 November 2019.
2. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. *Hepatology* **2013** ; 57:249–57.

- 442 3. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces
 443 hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
 444 Hepatology **2013** ; 58:98–107.
- 445 4. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the
 446 management of hepatitis B virus infection. J Hepatol **2017** ; 67:370–98.
- 447 5. Boyd A, Gozlan J, Mialhes P, et al. Rates and determinants of hepatitis B ‘e’ antigen and
 448 hepatitis B surface antigen seroclearance during long-term follow-up of patients
 449 coinfecting with HIV and hepatitis B virus: AIDS **2015** ; 29:1963–73.
- 450 6. Boyd A, Maylin S, Moh R, et al. Hepatitis B surface antigen quantification as a predictor of
 451 seroclearance during treatment in HIV-hepatitis B virus coinfecting patients from Sub-
 452 Saharan Africa: Seroclearance during treatment. J Gastroenterol Hepatol **2016** ; 31:634–
 453 44.
- 454 7. Boyd A, Maylin S, Gozlan J, et al. Use of hepatitis B surface and “e” antigen quantification
 455 during extensive treatment with tenofovir in patients co-infected with HIV-HBV. Liver Int
 456 **2015** ; 35:795–804.
- 457 8. Singh KP, Crane M, Audeley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus
 458 coinfection: epidemiology, pathogenesis, and treatment. AIDS **2017** ; 31:2035–52.
- 459 9. Chihota BV, Wandeler G, Chilengi R, et al. High Rates of Hepatitis B Virus (HBV)
 460 Functional Cure Among Human Immunodeficiency Virus-HBV Coinfecting Patients on
 461 Antiretroviral Therapy in Zambia. J Infect Dis **2019** ; jiz450.
- 462 10. Matthews GV, Ali RJ, Avihingsanon A, et al. Quantitative HBsAg and HBeAg Predict
 463 Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfecting Individuals.
 464 Tillmann H, editor. PLoS ONE **2013** ; 8:e61297.

- 465 11. Boyd A, Lacombe K, Lavocat F, et al. Decay of ccc-DNA marks persistence of intrahepatic
466 viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. *J Hepatol* **2016** ;
467 65:683–691.
- 468 12. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification
469 for monitoring natural history and treatment outcome. *Liver Int* **2013** ; 33:125–32.
- 470 13. Mak L-Y, Wong DK-H, Cheung K-S, Seto W-K, Lai C-L, Yuen M-F. Review article: hepatitis B
471 core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
472 *Aliment Pharmacol Ther* **2018** ; 47:43–54.
- 473 14. Wong DK-H, Tanaka Y, Lai C-L, Mizokami M, Fung J, Yuen M-F. Hepatitis B Virus Core-
474 Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection. *J Clin Microbiol*
475 **2007** ; 45:3942–47.
- 476 15. Tanaka E, Matsumoto A, Yoshizawa K, Maki N. Hepatitis B Core-Related Antigen Assay Is
477 Useful for Monitoring the Antiviral Effects of Nucleoside Analogue Therapy. *Intervirology*
478 **2008** ; 51:3–6.
- 479 16. Chen S, Jia J, Gao Y, et al. Clinical evaluation of hepatitis B core-related antigen in chronic
480 hepatitis B and hepatocellular carcinoma patients. *Clin Chim Acta* **2018** ; 486:237–44.
- 481 17. Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme
482 immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA
483 for monitoring lamivudine treatment. *J Viral Hepat* **2003** ; 10:324–30.
- 484 18. Chuaypen N, Posuwan N, Payungporn S, et al. Serum hepatitis B core-related antigen as a
485 treatment predictor of pegylated interferon in patients with HBeAg-positive chronic
486 hepatitis B. *Liver Int* **2016** ; 36:827–36.
- 487 19. Fan R, Sun J, Yuan Q, et al. Baseline quantitative hepatitis B core antibody titre alone
488 strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with
489 peginterferon or nucleos(t)ide analogues. *Gut* **2016** ; 65:313–20.

- 490 20. Lee BO, Tucker A, Frelin L, et al. Interaction of the Hepatitis B Core Antigen and the
491 Innate Immune System. *J Immunol* **2009** ; 182:6670–81.
- 492 21. Lacombe K, Massari V, Girard P-M, et al. Major role of hepatitis B genotypes in liver
493 fibrosis during coinfection with HIV: *AIDS* **2006** ; 20:419–27.
- 494 22. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by
495 an automated chemiluminescent microparticle immunoassay. *J Virol Methods* **2004** ;
496 115:217–22.
- 497 23. Maylin S, Boyd A, Martinot-Peignoux M, et al. Quantification of hepatitis B e antigen
498 between Elecsys HBeAg and Architect HBeAg assays among patients infected with
499 hepatitis B virus. *J Clin Virol* **2013** ; 56:306–11.
- 500 24. Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive Enzyme Immunoassay for Hepatitis B
501 Virus Core-Related Antigens and Their Correlation to Virus Load. *J Clin Microbiol* **2002** ;
502 40:439–45.
- 503 25. Yuan Q, Song L-W, Liu C-J, et al. Quantitative hepatitis B core antibody level may help
504 predict treatment response in chronic hepatitis B patients. *Gut* **2013** ; 62:182.2-184.
- 505 26. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using stata. Volume I:
506 Continuous responses. 3rd edition. College Station, Texas: StataCorp LP; 2012. 497 p.
- 507 27. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data
508 and a diagnostic marker. *Biometrics* **2000** ; 56:337–44.
- 509 28. Wang B, Carey I, Bruce M, Montague S, Dusheiko G, Agarwal K. HBsAg and HBcrAg as
510 predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide
511 analogues. *J Viral Hepat* **2018** ; 25:886–93.
- 512 29. Ma H, Yang R-F, Li X-H, Jin Q, Wei L. HBcrAg Identifies Patients Failing to Achieve HBeAg
513 Seroconversion Treated with Pegylated Interferon Alfa-2b: *Chin Med J* **2016** ; 129:2212–
514 19.

- 515 30. Lai C-L, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term
516 nucleos(t)ide analogue treatment in chronic hepatitis B. *J Hepatol* **2017** ; 66:275–81.
- 517 31. Hu H-H, Liu J, Chang C-L, et al. Level of Hepatitis B (HB) Core Antibody Associates With
518 Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative
519 Patients. *Clin Gastroenterol Hepatol* **2019** ; 17:172-181.e1.
- 520 32. Hou F-Q, Song L-W, Yuan Q, et al. Quantitative Hepatitis B Core Antibody Level Is a New
521 Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients
522 Receiving Peginterferon. *Theranostics* **2015** ; 5:218–26.
- 523 33. Liao H, Liu Y, Li X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels
524 in patients during long-term nucleoside/nucleotide analogue therapy. *Antivir Ther* **2019** ;
525 24:105-15.
- 526 34. Song L-W, Liu P-G, Liu C-J, et al. Quantitative hepatitis B core antibody levels in the
527 natural history of hepatitis B virus infection. *Clin Microbiol Infect* **2015** ; 21:197–203.
- 528 35. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis
529 B e antigen in patients with chronic hepatitis B infection. *Lancet* **1989** ; 2:588–91.
- 530 36. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus
531 genotype on the long-term outcome of chronic hepatitis B in western patients.
532 *Gastroenterology* **2002** ; 123:1848–56.
- 533 37. Campenhout MJH van, Brouwer WP, Oord GW van, et al. Hepatitis B core-related antigen
534 levels are associated with response to entecavir and peginterferon add-on therapy in
535 hepatitis B e antigen-positive chronic hepatitis B patients. *Clin Microbiol Infect Off Publ*
536 *Eur Soc Clin Microbiol Infect Dis* **2016** ; 22:571.e5–9.
- 537 38. Lin C-L, Kao J-H. Hepatitis B Virus Genotypes and Variants. *Cold Spring Harb Perspect*
538 *Med* **2015** ; 5:a021436–a021436.

- 539 39. Crane M, Sirivichayakul S, Chang JJ, et al. No Increase in Hepatitis B Virus (HBV)-Specific
540 CD8+ T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active
541 Antiretroviral Therapy. *J Virol* **2010** ; 84:2657–65.
- 542 40. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. *Hepatology* **2009** ;
543 49:S138–45.
- 544 41. Wang M-L, Liao J, Wei B, et al. Comparison of hepatitis B virus core-related antigen and
545 hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B
546 patients with pegylated interferon therapy. *Infect Dis* **2018** ; 50:522–30.
- 547 42. Maylin S, Boyd A, Lavocat F, et al. Kinetics of hepatitis B surface and envelope antigen
548 and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–
549 hepatitis B virus-infected patients: *AIDS* **2012** ; 26:939–49.
- 550 43. Boyd A, Maylin S, Gozlan J, et al. Use of hepatitis B surface and “e” antigen quantification
551 during extensive treatment with tenofovir in patients co-infected with HIV-HBV. *Liver Int*
552 **2015** ; 35:795–804.
- 553

Table 1. Baseline characteristics of patients treated with tenofovir

	HBeAg status		<i>p</i> ^a
	HBeAg-positive	HBeAg-negative	
	(<i>n</i> = 95)	(<i>n</i> = 63)	
Demographics			
Male sex ^b	89 (93.7)	44 (69.8)	<0.001
Age (years) ^c	40.3 (35.0-46.7)	41.6 (37.2-49.6)	0.26
From zone of high HBV-prevalence ^b	8 (8.4)	32 (50.8)	<0.001
BMI (Kg/m ²) ^c [<i>N</i> =153]	22.4 (20.9-23.9)	22.8 (21.0-25.8)	0.27
HIV infection			
Estimated duration of HIV infection, years ^c [<i>N</i> =157]	12.0 (7.7-15.3)	8.3 (5.0-14.4)	0.007
AIDS-defining event ^b	29 (30.5)	10 (15.9)	0.04
HIV-RNA (log ₁₀ copies/mL) ^c [<i>N</i> =157]	1.7 (1.7-4.0)	1.7 (1.7-3.2)	0.03
HIV-RNA > 50 copies/mL ^b [<i>N</i> =157]	45 (47.8)	22 (34.9)	0.11
CD4 ⁺ cell count (cells/μL) ^c [<i>N</i> =157]	423 (312-580)	388 (277-543)	0.24
Nadir CD4 ⁺ cell count (cells/μL) ^c [<i>N</i> =143]	230 (78-321)	212 (118-324)	0.9
Duration of ART (years) ^c	7.0 (4.8-9.2)	6.1 (3.2-9.0)	0.17
Viral hepatitis			
Estimated duration of HBV infection (years) ^c [<i>N</i> =157]	7.9 (3.8-11.8)	7.7 (3.6-13.1)	0.8
HBV-genotype ^b [<i>N</i> =104]			
A	55 (67.1)	13 (59.1)	0.5
D	7 (8.5)	1 (4.6)	0.5
E	4 (4.9)	8 (36.4)	<0.001
G	12 (14.6)	0 (0)	0.05

Precore mutation^b [N=101]	13 (15.9)	9 (47.4)	0.003
Concomitant LAM treatment ^b	67 (70.5)	39 (61.9)	0.26
HBV-DNA (log ₁₀ IU/mL) ^c [N=157]	6.6 (4.2-7.6)	1.9 (1.6-3.0)	<0.001
HBV-DNA <60 IU/mL ^b [N=157]	3 (3.2)	31 (49.2)	<0.001
ALT (IU/L) ^c [N=155]	63 (39-97)	28 (21-40)	<0.001
AST (IU/L) ^c [N=155]	44 (31-78)	27 (24-37)	<0.001
HBV serological markers			
qHBsAg (log₁₀ IU/mL)^c [N=157]	4.7 (4.3-5.1)	3.5 (3.3-3.9)	<0.001
qHBeAg level (PEIU/mL) ^c [N=70]	862 (328-1099)		
qHBcrAg level (log ₁₀ U/mL) ^c	7.8 (7.0-8.2)	3.0 (2.5-4.0)	<0.001
qAnti-HBc level (log ₁₀ PEIU/mL) ^c	2.8 (1.1-4.0)	3.4 (3.0-3.9)	0.008

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ART, antiretroviral treatment; BMI, body mass index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LAM, lamivudine; PEIU, Paul Ehrlich Institute units; qAnti-HBc, quantified anti-hepatitis B core antibody; qHBcrAg, quantified hepatitis B core-related antigen; qHBeAg, quantified hepatitis B e antigen; qHBsAg, quantified hepatitis B surface antigen.

^aComparing HBeAg-positive versus HBeAg-negative patients; significance determined using Kruskal–Wallis test for continuous variables and Pearson’s X²-test or Fisher’s exact test for categorical variables.

^bNumber (%).

^cMedian (25–75th percentile).

Table 2. Baseline determinants of hepatitis B core-related antigen and anti-hepatitis B core antibody

	qHBcrAg (log ₁₀ U/mL)						qAnti-HBc (log ₁₀ PEIU/mL)					
	Univariable			Multivariable			Univariable			Multivariable		
	Coef.	(95% CI)	<i>p</i>	Coef.	(95% CI)	<i>p</i>	Coef.	(95% CI)	<i>p</i>	Coef.	(95% CI)	<i>p</i>
Age (per year)	-0.047	(-0.092, -0.002)	0.04				0.031	(0.002, 0.061)	0.04	0.023	(-0.004, 0.051)	0.09
Sex (male)	2.084	(1.115, 3.052)	<0.001				-0.242	(-0.908, 0.424)	0.5			
From zone of high HBV-prevalence ^a	-2.545	(-3.303, -1.786)	<0.001				0.605	(0.053, 1.157)	0.03			
BMI (per kg/m ²) [<i>N</i> =153]	-0.099	(-0.225, 0.027)	0.12				-0.018	(-0.103, 0.066)	0.7			
AIDS-defining illness	0.915	(0.061, 1.768)	0.04	0.555	(-0.025, 1.135)	0.06	-0.743	(-1.295, -0.191)	0.009	-0.523	(-1.039, -0.007)	0.047
HIV-infection duration (per year) [<i>N</i> =157]	0.064	(-0.006, 0.134)	0.07				-0.005	(-0.052, 0.041)	0.8			
HBV-infection duration (per year) [<i>N</i> =157] ^a	-0.062	(-0.124, -0.0001)	0.05				0.031	(-0.010, 0.072)	0.14			
HIV-RNA (per log ₁₀ copies/mL) [<i>N</i> =157]	0.232	(-0.069, 0.533)	0.13				-0.226	(-0.421, 0.032)	0.02			
CD4 cell count [<i>N</i> =157]												
per 100 /mm ³	0.016	(-0.143, 0.175)	0.8				0.193	(0.094, 0.292)	<0.001	0.198	(0.105, 0.292)	<0.001
> 350 /mm ³	0.279	(-0.504, 1.061)	0.5				0.432	(-0.074, 0.938)	0.09			
CD4 nadir (> 250 cells/mm ³) [<i>N</i> =143]	0.203	(-0.602, 1.009)	0.6				0.520	(0.022, 1.018)	0.04			
Duration of ART (per year)	-0.040	(-0.143, 0.062)	0.4				0.015	(-0.052, 0.082)	0.7			
Concomitant LAM treatment	0.477	(-0.314, 1.268)	0.24				-0.344	(-0.859, 0.171)	0.19			

Cumulative LAM duration (per year)	0.074	(-0.050, 0.197)	0.24				0.005	(-0.075, 0.086)	0.9			
HBeAg-positive ^a	4.153	(3.765, 4.540)	<0.001				-0.949	(-1.423, -0.475)	<0.001	-0.943	(-1.399, -0.487)	<0.001
<i>Precore</i> mutation [N=101]	-0.724	(-1.643, 0.196)	0.12				-0.591	(-1.424, 0.241)	0.16			
HBV-DNA (per log ₁₀ IU/mL) [N=157]	0.726	(0.621, 0.831)	<0.001	0.622	(0.507, 0.737)	<0.001	-0.029	(-0.130, 0.073)	0.6			
ALT (per IU/mL) [N=155]	0.010	(0.006, 0.014)	<0.001				0.001	(-0.001, 0.004)	0.4			
AST (per IU/mL) [N=155]	0.024	(0.015, 0.032)	<0.001				0.001	(-0.005, 0.007)	0.8			
ALT ≤ 70 IU/mL [N=155]	-2.680	(-3.423, -1.937)	<0.001	-1.145	(-1.776, -0.513)	<0.001	0.277	(-0.283, 0.837)	0.3			
AST ≤ 70 IU/mL [N=155]	-2.639	(-3.527, -1.751)	<0.001				0.201	(-0.443, 0.844)	0.5			
qHBsAg level (log ₁₀ IU/mL) [N=157]	1.535	(1.246, 1.824)	<0.001				-0.160	(-0.406, 0.087)	0.20			
qHBeAg level (log ₁₀ PEIU/mL) [N=70]	0.571	(0.269, 0.873)	<0.001				0.0001	(-0.001, 0.001)	0.8			

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ART, antiretroviral treatment; BMI, body mass index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LAM, lamivudine; PEIU, Paul Ehrlich Institute units; qAnti-HBc, quantified anti-hepatitis B core antibody; qHBcrAg, quantified hepatitis B core-related antigen; qHBeAg, quantified hepatitis B e antigen; qHBsAg, quantified hepatitis B surface antigen.

^aThe following variables were not considered in multivariable analysis: *both models* – HBV and HIV-infection duration (unable to assess true infection duration), zone of HBV-prevalence, sex (collinear with other variables), AST ≤ 70 IU/mL (preferred over other transaminase variables) and HIV RNA (no longer below *p*-value threshold); qHBcrAg – HBeAg status, *precure* mutation and qHBsAg (collinearity) ; qAnti-HBc –CD4+ nadir >250/mm³, concomitant LAM treatment, and *precure* mutation (no longer below *p*-value threshold).

Table 3. Kinetics of hepatitis core-related antigen and anti-hepatitis B core antibody during follow-up

	Decline in qHBcrAg log ₁₀ U/mL per month ^a						Decline in qAnti-HBc log ₁₀ PEIU/mL per month ^a			
	HBeAg+				HBeAg-		HBeAg+		HBeAg-	
	≤18 months	<i>p</i> for	>18 months	<i>p</i> for				<i>p</i> for		<i>p</i> for
	Δ (95% CI)	intx ^a	Δ (95% CI)	intx	Δ (95% CI)	intx	Δ (95% CI)	intx	Δ (95% CI)	intx
Overall	<i>N</i> = 95				<i>N</i> = 63		<i>N</i> =95		<i>N</i> =63	
	-0.051 (-0.062, -0.040)		-0.011 (-0.024, 0.003)		-0.003 (-0.006, -0.001)		-0.011 (-0.013, -0.009)		-0.011 (-0.013, -0.009)	
HBV genotype	<i>N</i> = 82				<i>N</i> = 22		<i>N</i> =82		<i>N</i> =22	
A	-0.054 (-0.068, -0.040)	0.9	-0.068 (-0.090, -0.045)	0.29	0.001 (-0.006, 0.008)	0.01	-0.014 (-0.016, -0.012)	0.02	-0.005 (-0.011, 0.001)	0.6
D	-0.024 (-0.064, 0.017)	0.12	-0.038 (-0.054, -0.021)	0.4	-0.018 (-0.029, -0.008)	<0.001	-0.009 (-0.014, -0.003)	0.08	-0.002 (-0.012, 0.008)	0.4
E	-0.041 (-0.092, 0.011)	0.7	-0.041 (-0.060, -0.019)	0.9	-0.003 (-0.015, 0.008)	0.9	-0.013 (-0.020, -0.005)	0.9	-0.011 (-0.021, -0.002)	0.17
G	-0.075 (-0.117, -0.034)	0.27	-0.049 (-0.065, -0.033)	0.24	-		-0.013 (-0.018, -0.008)	0.9	-	-
YMDD mutation ^b	<i>N</i> = 82	0.17		0.07	<i>N</i> = 21		<i>N</i> =82	0.6	<i>N</i> =21	
Yes	-0.070 (-0.094, -0.046)		-0.044 (-0.060, -0.028)		-		-0.014 (-0.018, -0.011)		-	-
No	-0.051 (-0.065, -0.036)		-0.011 (-0.015, -0.007)		-0.004 (-0.010, 0.002)		-0.014 (-0.016, -0.011)		-0.070 (-0.132, -0.008)	
Precore mutation ^c	<i>N</i> = 82	0.3		0.9	<i>N</i> = 19	0.009	<i>N</i> =82	0.5	<i>N</i> =19	0.3
Yes	-0.048 (-0.083, -0.014)		-0.049 (-0.064, -0.033)		-0.007 (-0.014, -0.001)		-0.012 (-0.016, -0.007)		-0.004 (-0.010, 0.002)	
No	-0.053 (-0.067, -0.040)		-0.011 (-0.014, -0.007)		0.005 (-0.003, 0.014)		-0.013 (-0.016, -0.011)		-0.009 (-0.017, -0.001)	

Baseline CD4 ⁺ cell count	<i>N</i> = 95	0.6	0.9	<i>N</i> = 62	0.06	<i>N</i> =95	0.001	<i>N</i> =62	0.006
>350 cells/mm ³	-0.052(-0.066, -0.038)			-0.002 (-0.006, 0.001)		-0.015 (-0.017, -0.012)		-0.010 (-0.013, -0.007)	
≤350 cells/mm ³	-0.046 (-0.064, -0.027)			-0.006 (-0.010, -0.003)		-0.010 (-0.013, -0.007)		-0.062 (-0.095, -0.030)	
Nadir CD4 ⁺ cell count	<i>N</i> =87	0.60	0.10	<i>N</i> =56	0.3	<i>N</i> =87	0.004	<i>N</i> =56	0.007
>200 cells/mm ³	-0.047 (-0.063, -0.031)			-0.004 (-0.008, -0.001)		-0.015 (-0.018, -0.013)		-0.009 (-0.012, -0.007)	
≤200 cells/mm ³	-0.053 (-0.069, -0.037)			-0.006 (-0.009, -0.003)		-0.011 (-0.014, -0.009)		-0.006 (-0.008, -0.004)	

HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; PEIU, Paul Ehrlich Institute units; qAnti-HBc, quantified anti-hepatitis B core antibody; qHBcrAg, quantified hepatitis B core-related antigen.

Decline in markers were determined using a mixed-effect linear model adjusted for baseline levels, body mass index, age, concomitant lamivudine treatment, cumulative treatment duration with lamivudine, HBV-DNA level and CD4⁺ cells count (if not stratified).

^a Slopes were compared between determinant groups, *p* values derived from a Wald X²- test of an interaction term (calculated as the cross-product between duration of tenofovir treatment and presence of determinant), which is included in a mixed-effect linear model with its individual components.

^b Mutation at position rtM204 of the *pol* gene.

^c Mutation in the nucleotide at position 1896 (G versus A) of the *precore* region.

Table 4 – Factors associated to HBeAg-seroclearance during follow-up

Risk-Factor	Univariable		Multivariable Model 1 ^a		Multivariable Model 2 ^b	
	HR (95%CI)	<i>p</i>	HR (95%CI) ^c	<i>p</i>	HR (95%CI)	<i>p</i>
Age at baseline (per year)	1.04 (0.99-1.09)	0.10				
Male versus female sex	1.77 (0.24-12.92)	0.6				
From zone of high HBV-prevalence	0.89 (0.17-4.78)	0.9				
BMI at baseline (per kg/m ²)	0.94 (0.82-1.06)	0.3				
AIDS-defining illness at baseline	1.35 (0.60-3.01)	0.5				
HIV-infection duration at baseline (per year)	0.99 (0.91-1.09)	0.9				
HBV infection duration at baseline (per year)	0.97 (0.91-1.04)	0.4				
HIV-RNA (per log ₁₀ copies/mL) ^d	1.00 (0.95-1.06)	0.9				
CD4 cell count ^d						
per 100mm ³	1.00 (0.99-1.01)	0.8				
>350/mm ³	1.06 (0.98-1.14)	0.16				
per 250/mm ³ change from prior visit	0.98 (0.96-1.01)	0.17	0.98 (0.96 – 1.00)	0.08		

Duration of ART (per year) ^d	1.00 (0.99-1.01)	0.3			
Concomitant LAM treatment ^d	1.01 (0.98-1.05)	0.4			
Cumulative LAM duration (per year) ^d	1.00 (0.99-1.01)	0.3			
HBV-DNA at baseline (per log ₁₀ IU/mL)	0.89 (0.73-1.08)	0.24			
HBV-DNA (per log ₁₀ IU/mL) ^d	1.01 (0.99-1.03)	0.32			
ALT (per 10 IU/mL) ^d	1.00 (0.99-1.01)	0.26			
Baseline qHBsAg level (log ₁₀ IU/mL)	0.46 (0.26-0.83)	0.009			
Baseline qHBeAg level <100 PEIU/mL	2.64 (0.99-7.05)	0.05			
Baseline qHBeAg level <10 PEIU/mL	6.64 (2.40-18.36)	<0.001			
Baseline qHBeAg level (per PEIU/mL)	0.47 (0.30-0.72)	0.001			
Baseline qHBcrAg level (per log ₁₀ U/mL)	0.49 (0.34-0.71)	<0.001	0.48 (0.33 – 0.70)	<0.001	
Baseline qAnti-HBc level (per log ₁₀ PEIU/mL)	1.49 (1.08-2.07)	0.02		1.49 (1.08-2.07)	0.02

ALT, alanine aminotransferase; ART, antiretroviral treatment; BMI, body mass index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HR, hazard ratio; LAM, lamivudine; PEIU, Paul

Ehrlich Institute units; qAnti-HBc, quantified anti-hepatitis B core antibody; qHBcrAg, hepatitis B core-related antigen; qHBeAg, quantified hepatitis B e antigen; qHBsAg, quantified hepatitis B surface antigen. Analysis on the 95 HBeAg-positive patients, among whom 26 had HBeAg-loss.

In multivariable analysis, qHBeAg and qHBsAg were not further considered as the intent was to study qHBcrAg and qAnti-HBc antibodies. Univariable HR are provided for comparison.

^a Model 1: the following variables were no longer below the *p*-value threshold – age at baseline and CD4 cell count >350/mm³

^b Model 2: the following variables were no longer below the p -value threshold – age at baseline, CD4 cell count $>350/\text{mm}^3$ and per $250/\text{mm}^3$ change from prior visit.

^c All HR are adjusted for the variables listed in the column.

^d Time-varying covariate

Table 5. Quantifiable HBV markers in predicting HBeAg seroclearance

		Classification Probabilities ^a											
		M24		M36		M48		M60		M72		M96	
		<i>n</i> =78		<i>n</i> =63		<i>n</i> =40		<i>n</i> =34		<i>n</i> =27		<i>n</i> =13	
Criteria	<i>N</i>	Se	Sp	Se	Sp	Se	Sp	Se	Sp	Se	Sp	Se	Sp
qHBcrAg (log ₁₀ U/mL)													
<7.5 at baseline	95	0.86	0.61	0.66	0.61	0.73	0.65	0.72	0.67	0.69	0.70	0.58	0.79
<6.5 at M12	95	0.82	0.67	0.77	0.68	0.71	0.70	0.69	0.72	0.70	0.76	0.60	0.87
<6.5 at M24	84	††	††	1	0.58	0.97	0.61	0.94	0.64	0.96	0.69	0.80	0.82
<6.5 at M36	76	††	††	††	††	1	0.42	1	0.44	1	0.48	0.85	0.58
qAnti-HBc (log ₁₀ PEIU/mL)													
≥4.1 at baseline	95	0.51	0.80	0.42	0.81	0.44	0.83	0.43	0.84	0.41	0.86	0.33	0.95
qHBcrAg <7.5 and qAnti-HBc ≥4.1	95	0.37	0.89	0.31	0.90	0.32	0.91	0.30	0.92	0.27	0.94	0.21	0.98
qHBcrAg <7.5 or qAnti-HBc ≥4.1	95	1	0.52	0.78	0.52	0.85	0.56	0.87	0.59	0.84	0.63	0.69	0.73
HBV-DNA criteria ^b													

HBV- at M12	95	0.92	0.60	0.76	0.61	0.77	0.64	0.68	0.64	0.63	0.66	0.53	0.72
HBV- at M24	84	††	††	1	0.33	1	0.35	1	0.37	1	0.41	0.92	0.52
HBV- at M36	76	††	††	††	††	1	0.17	1	0.18	1	0.20	0.91	0.22

HBV, hepatitis B virus; qAnti-HBc, quantified anti-hepatitis B core antibody; qHBcrAg, quantified hepatitis B core-related antigen

Analysis on 95 HBeAg-positive patients, among whom 26 had HBeAg seroclearance.

^a As sensitivity (Se) and specificity (Sp) are calculated from survival probabilities, all patients (*N*) are included in analysis.

^b HBV- was defined as <60 IU/mL

For information, the number of patients (*n*) considered (i.e. those not lost to follow-up or having HBeAg seroclearance) during each time-interval has been included.

†† Not evaluated

Figure legends

Figure 1.

Hepatitis B core-related antigen quantification (qHBcrAg) according to (A) hepatitis B e antigen (HBeAg) status at tenofovir (TDF)-initiation, (B) cumulative probability of HBeAg seroclearance, (C) hepatitis B surface antigen (HBsAg) seroclearance during follow-up. Individual levels are expressed as grey lines.

Figure 2.

Anti-hepatitis B core antibodies quantification (qAnti-HBc) according to (A) hepatitis B e antigen (HBeAg) status at tenofovir (TDF)-initiation, (B) cumulative probability of HBeAg seroclearance, and (C) hepatitis B surface antigen (HBsAg) seroclearance during follow-up. Individual levels are expressed as grey lines.

Figure 1

Figure 2

Supplementary Figure 1. Selection of patients for analysis

Supplementary Table 1. Baseline characteristics of patients with and without HBsAg-seroclearance

	HBsAg seroclearance (<i>n</i> = 5)	No HBsAg seroclearance (<i>n</i> = 153)	<i>p</i> ^a
Male sex ^b	4 (80.0)	129 (84.3)	0.8
Age (years) ^c	43.2 (35.4-48.3)	41.1 (36.0-47.9)	0.6
From zone of high HBV-prevalence ^b	1 (20.0)	39 (25.5)	0.8
BMI (Kg/m ²) ^c [<i>N</i> =153]	22.1 (21.4-23.9)	22.6 (20.9-24.6)	0.9
AIDS-defining event ^b	1 (20.0)	38 (24.8)	0.8
CD4 ⁺ cell count (cells/μL) ^c [<i>N</i> =157]	316 (303-405)	405 (294-559)	0.3
Nadir CD4 ⁺ cell count (cells/μL) ^c [<i>N</i> =143]	194 (129-281)	227 (103-321)	0.6
Duration of ART (years) ^c	3.5 (1.1-7.5)	7.0 (4.4-9.0)	0.3
HBeAg-positive ^b	3 (60.0)	92 (60.1)	0.9
Estimated duration of HBV infection (years) ^c [<i>N</i> =157]	1.1 (0.8-7.4)	8.2 (3.7-12.4)	0.11
HBV-DNA (log ₁₀ IU/mL) ^c [<i>N</i> =157]	2.7 (2.3-6.1)	4.0 (2.2-6.6)	0.9
qHBsAg (log ₁₀ IU/mL) ^c [<i>N</i> =157]	2.9 (2.6-5.1)	4.3 (3.5-4.8)	0.4
qHBeAg level (PEIU/mL) ^c [<i>N</i> =70] ^d	1036 (236-1094)	779 (328-1099)	0.9
qHBcrAg level (log ₁₀ U/mL) ^c	6.7 (4-8)	6.8 (3.4-7.9)	0.8
qAnti-HBc level (log ₁₀ PEI U/mL) ^c	3.2 (1.7-3.6)	3.3 (2.2-4.0)	0.9

ART, antiretroviral treatment; BMI, body mass index; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen;

HBV, hepatitis B virus; PEIU, Paul-Ehrlich Institut units; qAnti-HBc, quantified anti-hepatitis B core antibody; qHBcrAg,

quantified hepatitis B core-related antigen; qHBeAg, quantified hepatitis B e antigen; qHBsAg, quantified hepatitis B surface antigen.

^aComparing patients with and without HBsAg-seroclearance; significance determined using Kruskal–Wallis test for continuous variables and Pearson’s χ^2 -test or Fisher’s exact test for categorical variables.

^bNumber (%).

^cMedian (25–75th percentile).

^dOnly for HBeAg-positive patients